Octapharma

Octapharma, established in 1983, is a global leader in the biotechnology and pharmaceutical sectors, specializing in the development and production of essential human proteins derived from human plasma and cell lines. Headquartered in Lachen, Switzerland, the company operates within the healthcare industry, focusing on critical therapeutic areas. Its commitment to innovation and patient care drives its extensive research and development efforts.

With a workforce exceeding 10,000 employees across its 5 locations, Octapharma manufactures a range of vital biopharmaceutical products. These include human protein therapies, plasma-derived medicines, and immunoglobulins (IVIG), crucial for treating various diseases and intensive care needs. The company's state-of-the-art facilities ensure the production of high-purity, safe, and effective treatments. Meet Octapharma's team to understand the expertise behind these life-saving innovations.

Octapharma generates significant revenue, reported at $2.7B, underscoring its substantial market presence and financial stability. The company's product portfolio addresses critical patient needs, offering advanced therapies and medicines that contribute to improved health outcomes worldwide. Its strategic focus on biopharmaceutical development positions it as a key player in advancing medical science and patient treatment experiences.